Transforming Lives

Through a new class of safe, durable cancer treatments.

Our Team

Our drug development team has a proven record of translating promising discoveries into therapeutics that profoundly change medical practice.
Learn more
Our Science

Our approach uses a new class of compounds called imipridones to selectively target G protein-coupled receptors (GPCRs) that control critical signaling pathways in cancer.
Learn more
Alliances

Rutgers Cancer Institute of N.J., MD Anderson Cancer Center and Mass. General Hospital/Dana Farber Cancer Institute are conducting ONC201 clinical trials.
Learn more

Learn More About ONC201 Clinical Trials

In The News

- MAR 21 2018
Fox Chase Cancer Center Researchers Uncover ONC201 Immune-oncology Effects
“Immune cell activation in the tumor and inhibition of metastasis with an oral, infrequently administered and well tolerated small molecule provides an attractive treatment option for patients. Immune activation is recognized as an important requirement to achieve durable and complete remissions in conjunction with standard-of-care therapies,” said El-Deiry. “We discovered ONC201 through its ability to

Read >

- JAN 25 2018
OncologyTube interviewed Dr. Anderson to talk about his ONC201 trial
In the videos below, Dr. Peter Anderson talks about ONC201 and his Phase II – Neuroendocrine Tumors (NCT03034200) at The Cleveland Clinic. The clinical trial is evaluating ONC201 in patients with neuroendocrine tumors. These tumors are known to overexpress DRD2, the target that ONC201 utilizes to drive its anti-cancer effects. Dr. Peter Anderson is the

Read >